A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy

被引:13
作者
Eoh, Kyung Jin [1 ]
Yoon, Jung Won [1 ]
Lee, Jung-Yun [1 ]
Nam, Eun Ji [1 ]
Kim, Sunghoon [1 ]
Kim, Sang Wun [1 ]
Kim, Young Tae [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Inst Womens Med Life Sci, 50-1 Yonsei Ro, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
Epithelial ovarian cancer; Laparoscopy; Cytoreduction surgical procedures; Debulking surgical procedures; SUBOPTIMAL PRIMARY CYTOREDUCTION; SURGERY; TOMOGRAPHY; CARCINOMA; CHEMOTHERAPY; VALIDATION; PREDICTORS; WOMEN; SCORE;
D O I
10.1186/s12885-017-3476-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study aimed to evaluate the perioperative outcomes and prognostic impact of the consecutive steps of imaging, frailty assessment, and diagnostic laparoscopy (DLS) in patients with advanced epithelial ovarian cancer (EOC). Methods: Patients diagnosed with EOC during 2012-2015 were analyzed retrospectively. Surgical and survival outcomes were compared between three treatment groups: patients without high tumor dissemination (HTD) who underwent primary debulking surgery (PDS group); patients with HTD who underwent DLS (DLS group); and patients with HTD diagnosed by cytological confirmation of malignancy followed by neoadjuvant chemotherapy (NACT group). Results: Of 181 patients, 85, 38, and 58 underwent PDS, DLS, and NACT, respectively. Among the 38 consecutive patients who initially underwent DLS, 6 were considered suitable for PDS; the remaining 32 were eligible for NACT followed by interval debulking surgery. The median operative times of debulking surgery in the PDS, DLS, and NACT groups were 365 min (interquartile range [ IQR]: 216.5-476.5 min), 266.2 min (IQR: 160.3-193. 5 min), and 339.0 min (IQR: 205-425 min; P = 0.042), respectively, with respective median estimated blood loss volumes of 962.2 mL (IQR: 300-1037.5 mL), 267.1 mL (IQR: 150-450 mL), and 861.7 mL (IQR: 150-1200 mL; P = 0.023). The DLS group had significantly reduced transfusion requirements and intensive care unit admission rates (P = 0.006). The Kaplan-Meier survival analysis indicated significantly poor PFS in the NACT group. However, there was no significant difference in OS among the three groups. Conclusions: The consecutive steps of imaging, frailty assessment, and DLS might facilitate rapid assessments of peritoneal disease extent and resectability; this novel algorithm might also be used to individualize treatment.
引用
收藏
页数:7
相关论文
共 26 条
[1]   Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment [J].
Aletti, Giovanni D. ;
Eisenhauer, Eric L. ;
Santillan, Antonio ;
Axtell, Allison ;
Aletti, Giacomo ;
Holschneider, Christine ;
Chi, Dennis S. ;
Bristow, Robert E. ;
Cliby, William A. .
GYNECOLOGIC ONCOLOGY, 2011, 120 (01) :23-28
[2]   Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer [J].
Axtell, Allison E. ;
Lee, Margaret H. ;
Bristow, Robert E. ;
Dowdy, Sean C. ;
Cliby, William A. ;
Raman, Steven ;
Weaver, John P. ;
Gabbay, Mojan ;
Ngo, Michael ;
Lentz, Scott ;
Cass, Ilana ;
Li, Andrew J. ;
Karlan, Beth Y. ;
Holschneider, Christine H. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (04) :384-389
[3]   Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer [J].
Brockbank, EC ;
Ind, TEJ ;
Barton, DPJ ;
Shepherd, JH ;
Gore, ME ;
A'Hern, R ;
Bridges, JE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (01) :42-50
[4]   External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers:: Clues for a simplified score [J].
Brun, Jean-Luc ;
Rouzier, Roman ;
Uzan, Serge ;
Darai, Emile .
GYNECOLOGIC ONCOLOGY, 2008, 110 (03) :354-359
[5]   The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma [J].
Chi, DS ;
Venkatraman, ES ;
Masson, V ;
Hoskins, WJ .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :227-231
[6]   Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial [J].
Crawford, SC ;
Vasey, PA ;
Paul, J ;
Hay, A ;
Davis, JA ;
Kaye, SB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8802-8811
[7]   The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma [J].
Dowdy, SC ;
Mullany, SA ;
Brandt, KR ;
Huppert, BJ ;
Cliby, WA .
CANCER, 2004, 101 (02) :346-352
[8]   Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].
du Bois, Andreas ;
Reuss, Alexander ;
Pujade-Lauraine, Eric ;
Harter, Philipp ;
Ray-Coquard, Isabelle ;
Pfisterer, Jacobus .
CANCER, 2009, 115 (06) :1234-1244
[9]   Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study [J].
Eisenkop, SM ;
Friedman, RL ;
Wang, HJ .
GYNECOLOGIC ONCOLOGY, 1998, 69 (02) :103-108
[10]  
Elattar A, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007565.pub2, 10.1002/14651858.CD007565]